At ALLpaQ, we boast an unwavering commitment to quality – not only in our products but also in our people. […]
Dec 05th, 2023
Dec 05th, 2023
Bioprocessing news: The global single use bioreactors market looks set to expand at a two-fold compound annual growth rate over the next five years, according to a report by Research and Markets.
Back in 2014, the single use bioreactor market generated $202.5 million. This, says the report, could grow 18.4% to reach $470.9 million by 2019.
A single use bioreactor – or disposable bioreactor – is a bioreactor which harnesses disposable bags rather than a culture vessel.
The market expansion of single use bioreactors is being driven by a number of factors including the increasing deployment of the technology in developing markets such as China and India.
Research and Markets’ report segments the global single use bioreactors by molecule type, type of cell, technology, end user and region.
On their website, they explain: “The monoclonal antibodies (MAbs) segment accounted for the lion’s share of the global SUB market, by molecule type. However, the stem cell segment is expected to grow at the highest CAGR in the forecast period, owing to an increased focus on research in this segment.
“On the basis of type of cell, the SUB market is categorized into mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell). The mammalian cell segment is expected to be the new revenue pocket in the market by type of cell. Increasing numbers of biologics are being based on mammalian cells due to their increased compatibility and bioactivity in humans.”
“The technology segment,” continues Research and Markets, “is subsegmented into wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors and others (single-use reactors with vertically perforated discs and single-use hybrid reactors). Wave-induced motion SUB technology is the oldest and most widely accepted of these, which accounts for its large market share.
“Research and development (R&D) of biopharmaceutical manufacturers, research institutes and contract research organizations (CROs) are the major end users of the SUB, followed by biopharmaceutical manufacturing. The large share of the R&D segment can be attributed to the wide acceptance of SUBs for small – and mid-scale biopharmaceutical manufacturing for clinical testing and R&D. New and innovative product launches were found to be the dominant strategy adopted by key industry participants to increase their market share and cater to unmet market needs.”
Key topics areas covered in Research and Markets’ single use bioreactor report, include: